{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:52Z","timestamp":1792510132483,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00198-018-4642-2","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T16:59:49Z","timestamp":1532192389000},"page":"2557-2564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The tamoxifen paradox\u2014influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-5818","authenticated-orcid":false,"given":"I.","family":"Kyvernitakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,21]]},"reference":[{"issue":"6","key":"4642_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67(6):439\u2013448","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4642_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ctrv.2007.04.005","volume":"33","author":"H Ding","year":"2007","unstructured":"Ding H, Field TS (2007) Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev 33(6):506\u2013513","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"4642_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326(13):852\u2013856","journal-title":"N Engl J Med"},{"issue":"5","key":"4642_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000368843","volume":"9","author":"M Kalder","year":"2014","unstructured":"Kalder M, Hadji P (2014) Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care (Basel) 9(5):312\u2013317","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"4642_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jocd.2013.03.003","volume":"17","author":"M Kalder","year":"2014","unstructured":"Kalder M, Hans D, Kyvernitakis I, Lamy O, Bauer M, Hadji P (2014) Effects of exemestane and tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. J Clin Densitom 17(1):66\u201371","journal-title":"J Clin Densitom"},{"issue":"6","key":"4642_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE et al (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38(6):798\u2013806","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"4642_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/jnci\/81.14.1086","volume":"81","author":"S Turken","year":"1989","unstructured":"Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R (1989) Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81(14):1086\u20131088","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"4642_CR8","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4642_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3322\/caac.20103","volume":"61","author":"A VanderWalde","year":"2011","unstructured":"VanderWalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61(3):139\u2013156","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4642_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/jbmr.1556","volume":"27","author":"LJ Melton 3rd","year":"2012","unstructured":"Melton LJ 3rd, Hartmann LC, Achenbach SJ, Atkinson EJ, Therneau TM, Khosla S (2012) Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res 27(5):1196\u20131205","journal-title":"J Bone Miner Res"},{"issue":"5","key":"4642_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM et al (2005) Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 165(5):552\u2013558","journal-title":"Arch Intern Med"},{"issue":"5","key":"4642_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00223-008-9132-7","volume":"82","author":"P Vestergaard","year":"2008","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2008) Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int 82(5):334\u2013340","journal-title":"Calcif Tissue Int"},{"key":"4642_CR13","unstructured":"Ogdie A LS, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Pharmacoepidemiology.In: Strom BLKS, Hennessy S (eds). University of Pennsylvania"},{"issue":"1","key":"4642_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00198-016-3714-4","volume":"28","author":"I Kyvernitakis","year":"2017","unstructured":"Kyvernitakis I, Kostev K, Nassour T, Thomasius F, Hadji P (2017) The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos Int 28(1):291\u2013297","journal-title":"Osteoporos Int"},{"issue":"7","key":"4642_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/1471301215621854","volume":"16","author":"J Bohlken","year":"2017","unstructured":"Bohlken J, Jacob L, Schaum P, Rapp MA, Kostev K (2017) Hip fracture risk in patients with dementia in German primary care practices. Dementia (London) 16(7):853\u2013864","journal-title":"Dementia (London)"},{"issue":"1","key":"4642_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-015-3661-3","volume":"155","author":"N Schmidt","year":"2016","unstructured":"Schmidt N, Jacob L, Coleman R, Kostev K, Hadji P (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155(1):151\u2013157","journal-title":"Breast Cancer Res Treat"},{"key":"4642_CR17","first-page":"17","volume":"9","author":"S Pscherer","year":"2016","unstructured":"Pscherer S, Kostev K, Dippel FW, Rathmann W (2016) Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care. Diabetes Metab Syndr Obes 9:17\u201323","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"4642_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00198-015-3246-3","volume":"27","author":"BJ Edwards","year":"2016","unstructured":"Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM et al (2016) Elevated incidence of fractures in women with invasive breast cancer. Osteoporos Int 27(2):499\u2013507","journal-title":"Osteoporos Int"},{"issue":"4","key":"4642_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00198-008-0721-0","volume":"20","author":"Z Chen","year":"2009","unstructured":"Chen Z, Maricic M, Aragaki AK, Mouton C, Arendell L, Lopez AM et al (2009) Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women\u2019s Health Initiative. Osteoporos Int 20(4):527\u2013536","journal-title":"Osteoporos Int"},{"issue":"1","key":"4642_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/02841860802167490","volume":"48","author":"P Vestergaard","year":"2009","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2009) Fracture risk in patients with different types of cancer. Acta Oncol 48(1):105\u2013115","journal-title":"Acta Oncol"},{"issue":"10","key":"4642_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S1047-2797(03)00056-5","volume":"13","author":"EB Lamont","year":"2003","unstructured":"Lamont EB, Lauderdale DS (2003) Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 13(10):698\u2013703","journal-title":"Ann Epidemiol"},{"key":"4642_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/bonekey.2015.60","volume":"4","author":"P Hadji","year":"2015","unstructured":"Hadji P (2015) Cancer treatment-induced bone loss in women with breast cancer. Bonekey Rep 4:692","journal-title":"Bonekey Rep"},{"issue":"14","key":"4642_CR23","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 19(14):3306\u20133311","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"4642_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/13697137.2014.929105","volume":"18","author":"I Kyvernitakis","year":"2015","unstructured":"Kyvernitakis I, Albert US, Kalder M, Winarno AS, Hars O, Hadji P (2015) Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer. Climacteric 18(1):63\u201368","journal-title":"Climacteric"},{"issue":"10","key":"4642_CR25","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00432-014-1726-z","volume":"140","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P (2014) Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol 140(10):1671\u20131680","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"4642_CR26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28(7):2023\u20132034","journal-title":"Osteoporos Int"},{"key":"4642_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY et al (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"issue":"32","key":"4642_CR28","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1200\/JCO.2007.15.7123","volume":"26","author":"AL Cooke","year":"2008","unstructured":"Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD (2008) Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 26(32):5227\u20135232","journal-title":"J Clin Oncol"},{"issue":"2","key":"4642_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0021-9681(87)90061-0","volume":"40","author":"JP Utz","year":"1987","unstructured":"Utz JP, Melton LJ 3rd, Kan SH, Riggs BL (1987) Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study. J Chronic Dis 40(2):105\u2013113","journal-title":"J Chronic Dis"},{"issue":"3","key":"4642_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF01806160","volume":"39","author":"B Kristensen","year":"1996","unstructured":"Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB (1996) Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 39(3):321\u2013326","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"4642_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7):637\u2013645","journal-title":"JAMA"},{"issue":"1","key":"4642_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/mol.54.1.105","volume":"54","author":"T Barkhem","year":"1998","unstructured":"Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists\/antagonists. Mol Pharmacol 54(1):105\u2013112","journal-title":"Mol Pharmacol"},{"issue":"1","key":"4642_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/toxsci\/54.1.138","volume":"54","author":"RM Blair","year":"2000","unstructured":"Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL et al (2000) The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 54(1):138\u2013153","journal-title":"Toxicol Sci"},{"issue":"1","key":"4642_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF01880410","volume":"1","author":"C Christiansen","year":"1990","unstructured":"Christiansen C, Lindsay R (1990) Estrogens, bone loss and preservation. Osteoporos Int 1(1):7\u201313","journal-title":"Osteoporos Int"},{"issue":"7\u20138","key":"4642_CR35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","volume":"79","author":"JA Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79(7\u20138):1179\u20131181","journal-title":"Br J Cancer"},{"issue":"9","key":"4642_CR36","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20(9):1489\u20131498","journal-title":"Ann Oncol"},{"issue":"12","key":"4642_CR37","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22(12):2546\u20132555","journal-title":"Ann Oncol"},{"key":"4642_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.bone.2018.06.007","volume":"114","author":"I Kyvernitakis","year":"2018","unstructured":"Kyvernitakis I, Kann PH, Thomasius F, Hars O, Hadji P (2018) Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone 114:109\u2013115","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-018-4642-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-018-4642-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T19:12:29Z","timestamp":1563649949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-018-4642-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,21]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4642"],"URL":"https:\/\/doi.org\/10.1007\/s00198-018-4642-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,21]]},"assertion":[{"value":"29 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}